InflaRx N.V Total Assets
InflaRx N.V total assets. Based on the latest financial reports, InflaRx N.V (IF0) holds total assets worth €55.22 Million EUR (≈ $64.55 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see InflaRx N.V market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of InflaRx N.V (2016–2025)
Total assets of InflaRx N.V from 2016 to 2025. This chart illustrates how InflaRx N.V's total assets have evolved over time, based on quarterly financial data. See IF0 stock price for real-time trading data and today's change.
InflaRx N.V - Asset Composition Analysis
InflaRx N.V Total Assets Breakdown (December 2025)
InflaRx N.V total assets breakdown as of December 2025. InflaRx N.V's total assets of €55.22 Million consist of 97.1% current assets and 2.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 29.0% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €42.26K | 0.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how InflaRx N.V's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore IF0 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: InflaRx N.V's current assets represent 97.1% of total assets in 2025, a decrease from 99.5% in 2016.
- Cash Position: Cash and equivalents constituted 29.0% of total assets in 2025, down from 98.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 0.1% of total assets.
InflaRx N.V Competitors by Total Assets
Key competitors of InflaRx N.V based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
InflaRx N.V - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.13 | 5.06 | 17.68 |
| Quick Ratio | 4.13 | 4.57 | 17.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €40.65 Million | €57.49 Million | €137.23 Million |
InflaRx N.V - Advanced Valuation Insights
This section examines the relationship between InflaRx N.V's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.61 |
| Latest Market Cap to Assets Ratio | 2.14 |
| Asset Growth Rate (YoY) | -27.4% |
| Total Assets | €55.22 Million |
| Market Capitalization | $117.99 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values InflaRx N.V's assets at a significant premium (2.14x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: InflaRx N.V's assets decreased by 27.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for InflaRx N.V (2016–2025)
The table below shows the annual total assets of InflaRx N.V from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €55.22 Million ≈ $64.55 Million |
-27.36% |
| 2024-12-31 | €76.02 Million ≈ $88.87 Million |
-36.76% |
| 2023-12-31 | €120.21 Million ≈ $140.54 Million |
+17.39% |
| 2022-12-31 | €102.40 Million ≈ $119.72 Million |
-18.17% |
| 2021-12-31 | €125.14 Million ≈ $146.30 Million |
+41.86% |
| 2020-12-31 | €88.22 Million ≈ $103.13 Million |
-27.44% |
| 2019-12-31 | €121.58 Million ≈ $142.14 Million |
-23.64% |
| 2018-12-31 | €159.21 Million ≈ $186.14 Million |
+28.18% |
| 2017-12-31 | €124.21 Million ≈ $145.22 Million |
+320.80% |
| 2016-12-31 | €29.52 Million ≈ $34.51 Million |
-- |
About InflaRx N.V
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinic… Read more